Brain tumors, the most common solid tumors of childhood, represent a significant cause of neurological morbidity and mortality. For medulloblastoma and other primitive neuroectodermal tumors (PNET) of the CNS, the biology, treatment and delayed neurotoxicities are poorly understood despite its recognized importance as the most common childhood brain tumor. Moreover, the specialized problems posed by childhood brain tumors are only partially addressed by current brain tumor research centers and a more focused commitment is required. Our proposal identifies two overall objectives designed to explore the feasibility of developing a pediatric brain tumor research center at The Children's Hospital of Philadelphia (CHOP). The first objective is to develop an integrated, coordinated network of investigators who will examine laboratory and clinical issues specific to PNET and relevant to other childhood brain tumors. This objective will be accomplished by the Aims for the Program as a Whole, including specific mechanisms to: (1) improve communication and interaction between investigators; (2) attract promising young investigators and entice established researchers to address pediatric neuro-oncology topics; and (3) encourage trainees to pursue careers as clinician-scientists in pediatric neuro-oncology research. The second objective is to increase our understanding of the biology, treatment and delayed toxicities of therapy by conducting innovative research. This objective will be accomplished by the following exploratory projects which, together, represent a comprehensive approach to PNET: Project 1 will address the role of protein tyrosine kinase growth factors in PNET differentiation and pathogenesis; Project 2 will examine signal transduction pathways (phospholipase C) in PNET, Project 3 will evaluate innovative therapeutic approaches to PNET and other childhood brain tumors; Project 4 will use innovative methodologies to address the functional biology, prevention and treatment of treatment-associated brain injury in long-term survivors of PNET. The Neuro-Oncology Program at CHOP has received recognition for its clinical contributions. This proposal addresses the need for integrated program development that includes basic sciences and experimental therapeutics. It is further enhanced by recent events at The Children's Hospital of Philadelphia and University of Pennsylvania, including new Program leadership, faculty recruitments, and construction of research facilities. Together with our large brain tumor population, institutional commitments to the specialized problems of children, strong research environment from the surrounding University, and on-site access to NIH-funded specialized research centers relevant to this proposal, these strengths make CHOP an ideal site to explore the feasibility of developing a specialized center for pediatric brain tumor research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory Grants (P20)
Project #
5P20NS031102-03
Application #
2269060
Study Section
Special Emphasis Panel (SRC (44))
Project Start
1992-09-30
Project End
1995-09-29
Budget Start
1994-09-30
Budget End
1995-09-29
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Janss, A J; Maity, A; Tang, C B et al. (2001) Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin. Neuro Oncol 3:11-21
Reddy, U R; Basu, A; Bannerman, P et al. (1999) ZPK inhibits PKA induced transcriptional activation by CREB and blocks retinoic acid induced neuronal differentiation. Oncogene 18:4474-84
Janss, A J; Levow, C; Bernhard, E J et al. (1998) Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines. Exp Cell Res 243:29-38
Janss, A J; Cnaan, A; Zhao, H et al. (1998) Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anticancer Drugs 9:641-52
Ingham, R J; Holgado-Madruga, M; Siu, C et al. (1998) The Gab1 protein is a docking site for multiple proteins involved in signaling by the B cell antigen receptor. J Biol Chem 273:30630-7
Biegel, J A; Janss, A J; Raffel, C et al. (1997) Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 3:473-8
Lawe, D C; Hahn, C; Wong, A J (1997) The Nck SH2/SH3 adaptor protein is present in the nucleus and associates with the nuclear protein SAM68. Oncogene 14:223-31
Emlet, D R; Moscatello, D K; Ludlow, L B et al. (1997) Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem 272:4079-86
Holgado-Madruga, M; Moscatello, D K; Emlet, D R et al. (1997) Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. Proc Natl Acad Sci U S A 94:12419-24
Reddy, U R; Phatak, S; Pleasure, D (1996) Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene 13:1555-9

Showing the most recent 10 out of 16 publications